InforMedix Holdings, Inc. (OTCBB: IFMX,
informedix), developer of the Med-eMonitor™, an
interactive smart pillbox system for medication adherence and health
management, is planning to introduce a new device, the Med-ePhone™.
InforMedix expects that the Med-ePhone system will provide a simple,
inexpensive method for reminding users to take their medications
regularly, and that the device will record and monitor patient medication
adherence and health status over mobile phones and landlines. The
Med-ePhone system is being designed to send patient- reported data to be
analyzed by proprietary software algorithms already operational in
InforMedix's Med-eXpert™ System which will then alert loved ones and/or
care managers when a patient's medications are missed or health declines.
Once Med-ePhone users are linked into the system, they will receive up to
three daily reminders. These reminders will be kept short and simple to
encourage high levels of user satisfaction, and will include prompts to
provide answers to simple health status queries. Six of InforMedix's
issued patents disclose the use of voice technologies to improve patient
medication adherence.
In addition to tracking patient adherence to their medication use and
health status, InforMedix expects that the Med-ePhone system will provide
healthcare professionals with automated real-time alerts when patients
miss their medications or their health declines.
"We designed Med-ePhone to be an entry-level product to complement our
Med-eMonitor," said Mike Gavin, Vice President of Research and
Development at InforMedix. "We anticipate that the Med-ePhone will be an
excellent solution for patients and their families for managing simpler
medication regimens while preserving the core features of the
Med-eMonitor System's prompting, monitoring, and reporting services."
Remie Smith, Vice President of Software Development at InforMedix
remarked, "What excites us about the Med-ePhone is that we will remotely
program it, monitor the patients, and report the urgent alerts through
our same Med-eXpert System, which has proven to be a highly reliable and
robust database and reporting engine."
"We expect that the Med-ePhone will be another important device in our
patient empowerment toolbox," said Bruce A. Kehr, MD, CEO of InforMedix.
"InforMedix's goal is to help people lead safe, productive, and
independent lives while bringing peace-of-mind to patients and their
loved ones. With Med-ePhone, we plan to continue to make medication use
safe and easy with an entry-level, mass-market product for patients on
simpler medication regimens. The Med-ePhone is being designed to
complement the Med-eMonitor's functionality, which provides a
comprehensive management system for the more complex patients, including
individualized alerts, instructions, and medication education and
monitoring for up to twenty-five different medications per patient. After
the planned launch, with two products at two price points, we believe
that InforMedix will be able to provide solutions for virtually every
conceivable medication adherence challenge."
Med-ePhone is currently under development and being tested. Upon
successful completion of testing, InforMedix expects to introduce it to
the consumer market through pharmacies in early 2008.
About InforMedix, Inc.
InforMedix, Inc., based in Rockville, Maryland, has developed the Med-
eMonitor™ and Med-ePhone™ System as The Medication Adherence Solution for
consumer product and disease management markets, to deliver peace-
of-mind, improved independent living, and better health outcomes to
patients and their loved ones. The Med-eMonitor System ("Medication, Safe
and Easy"™) integrates a portable patient-interactive "smart pillbox",
hardware, software, and call center monitoring. This is designed to
enable chronically ill patients and their loved ones, professionals in
disease management programs, and medical researchers to efficiently
monitor and manage patients' medication and care plan adherence, clinical
response, and drug safety.
informedix
Safe Harbor Statement
This press release may contain forward looking statements that involve
risks and uncertainties, including statements regarding our business
strategy and development plans, plans for entering into new businesses,
the anticipated introduction of new products, anticipated sources and
uses of funds and other statements regarding our plans, objectives,
expectations and intentions that are not historical facts. Because these
forward-looking statements involve risks and uncertainties, actual
results could differ materially from those discussed in this press
release. These risks and uncertainties are described in greater detail in
the reports that we file with the Securities and Exchange Commission. Our
actual results, performance or achievements may vary materially from
those expressed or implied in any forward-looking statements. All
forward-looking statements reflect our beliefs and expectations as of the
date of this press release and should not be relied upon as representing
our views as of any subsequent date. While we may elect to update these
forward- looking statements publicly at some point in the future, we
specifically disclaim any obligation to do so, whether as a result of new
information, future events or otherwise.
InforMedix, Inc.
Комментариев нет:
Отправить комментарий